Effects of Medical Treatment of ICAS With Hemodynamic Disorders Based on MR-FFR (NCT06196398) | Clinical Trial Compass
UnknownNot Applicable
Effects of Medical Treatment of ICAS With Hemodynamic Disorders Based on MR-FFR
China400 participantsStarted 2023-01-01
Plain-language summary
This multicenter prospective cohort study aims to compare the difference in the effects of medical treatment within 1 year between the two groups of ICAS patients divided hemodynamically by Magnetic Resonance Fractional Flow Reserve. PC MRA will be applied for FFR measurement. The primary outcome is the composite of ischemic stroke or death related to the qualifying artery territory for 1 year.
Who can participate
Age range
30 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients aged from 30 to 80 with symptomatic ICAS lesion in anterior circulation.
. 50% to 99% stenosis (in accordance with modified WASID method) confirmed by DSA, CTA or MRA.
. mRS 0-2 points
. Informed of the study protocol and objectives.
Exclusion criteria
. Previous endovascular treatment or surgery for cerebrovascular diseases
. Large cerebral infarction (more than 1/2 MCA perfusion area) according to MRI
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The composite of ischemic stroke or death related to the qualifying artery territory
. Combined with other neurological diseases, such as aneurysm, arteriovenous malformation, tumor, hydrocephalus, cerebral trauma, cerebral hemorrhage, multiple sclerosis, epilepsy and intracranial infection.
. Pregnancy or in the preparation for pregnancy
. Patients who cannot tolerate or do not allow MR screening, including metal implanting and claustrophobia
. Contraindication for antiplatelet drugs or statins
. Patients with severe dementia or mental disorders, who cannot cooperate with examination